What cybersecurity risks do CROs and third-party vendors create for biotech companies?
CROs, vendors, cloud providers, and research partners can introduce cybersecurity risks that affect research data, intellectual property, compliance obligations, and business operations. Third-party relationships frequently involve laboratory information management systems (LIMS), electronic laboratory notebooks (ELN), clinical data platforms, cloud applications, and research repositories. Effective third-party risk management helps biotech companies reduce exposure, strengthen oversight, and support secure collaboration across research and commercial activities.
Table of contents
Why do third-party vendors create cybersecurity risks for biotech companies?
Third-party vendors pose cybersecurity risks because they often gain access to sensitive data, cloud applications, laboratory systems, and business platforms that support critical operations. Many vendors connect directly to cloud platforms, identity systems, laboratory applications, and research environments, increasing the potential attack surface.
What is third-party cybersecurity risk?
Third-party cybersecurity risk refers to the potential for vendors, CROs, suppliers, contractors, cloud providers, or business partners to introduce security vulnerabilities, unauthorized access, compliance concerns, or operational disruptions that affect a biotech organization.
Common risk factors include:
- Excessive user permissions
- Weak access controls
- Inadequate security monitoring
- Poor vulnerability management
- Insufficient employee training
- Limited incident response capabilities
A security issue affecting a vendor can become a security issue for the biotech company that depends on that provider. Understanding third-party security practices helps reduce potential pathways to unauthorized access and operational disruption.
What cybersecurity risks do CROs introduce into biotech environments?
CROs can introduce risks related to data handling, access management, information sharing, and regulatory compliance. These organizations frequently work with research data, study information, laboratory records, and proprietary scientific assets. Risks may also extend to clinical trial data, manufacturing preparation records, and proprietary scientific workflows.
Potential concerns include:
- Unauthorized data exposure
- Misconfigured cloud environments
- Credential compromise
- Weak authentication practices
- Insufficient audit logging
- Third-party subcontractor risk
Many biotech organizations work with managed security providers, such as Single Point of Contact, to improve visibility into external relationships and strengthen oversight of vendor-connected environments. Better governance helps reduce uncertainty regarding third-party access and data-handling practices.
How do biotech companies secure research data shared with external collaborators?
Biotech companies secure research data shared with external collaborators through access governance, encryption, monitoring, and clearly defined data-sharing procedures.
Important safeguards include:
- Role-based access controls
- Multi-factor authentication
- Data encryption
- Audit trail retention
- Access reviews
- Secure file-sharing platforms
- Data loss prevention controls
- Time-limited access permissions
Research collaborations frequently involve CROs, academic institutions, manufacturing partners, and consulting firms. Providers, such as Single Point of Contact, may help organizations review data-sharing practices and identify opportunities to strengthen the protection of sensitive information. Well-managed collaboration environments support scientific progress while reducing the risk of intellectual property loss and unauthorized disclosure.
How can biotech companies evaluate third-party cybersecurity risk?
Biotech companies evaluate third-party cybersecurity risk through security reviews, risk assessments, questionnaires, contractual requirements, and ongoing oversight activities. Reviews should prioritize vendors that handle regulated information, intellectual property, clinical data, or critical business operations.
Evaluation areas commonly include:
- Security policies
- Incident response capabilities
- Compliance certifications
- Access management practices
- Vulnerability management programs
- Data protection controls
The chart below highlights common review categories.
Review area | Assessment focus | Risk consideration |
Access controls | User permissions | Unauthorized access |
Data protection | Sensitive information | Data exposure |
Incident response | Response readiness | Recovery capability |
Compliance | Regulatory obligations | Audit readiness |
Infrastructure | Technology environment | Operational resilience |
Vendor management | Subcontractor oversight | Extended risk exposure |
Structured assessments help organizations identify weaknesses before they become business risks.
What cybersecurity risks can delay biotech partnerships or licensing deals?
Cybersecurity risks can delay partnerships or licensing agreements when potential collaborators raise concerns about data protection, compliance, governance, or operational maturity. Investor diligence reviews increasingly evaluate cybersecurity readiness alongside scientific, operational, and financial factors.
Common issues include:
- Unresolved vulnerabilities
- Missing security policies
- Incomplete risk assessments
- Weak access controls
- Limited monitoring capabilities
- Poor documentation practices
Due diligence reviews increasingly include cybersecurity evaluations. Organizations that can demonstrate governance, oversight, and documented controls are often better positioned to move partnership discussions forward without unnecessary delays.
How should a biotech prepare for cyber insurance review?
Biotech companies preparing for cyber insurance reviews should evaluate security controls, documentation, governance practices, and incident response capabilities before engaging with insurers. Cyber insurers frequently evaluate multi-factor authentication, endpoint protection, backup testing, and incident response maturity when assessing risk.
Preparation activities typically include:
- Reviewing access controls
- Assessing endpoint protection
- Evaluating backup procedures
- Validating incident response plans
- Documenting security policies
- Completing risk assessments
Insurance providers frequently evaluate both technical safeguards and operational maturity. Organizations that maintain current documentation and evidence of ongoing oversight are generally better prepared for underwriting reviews.
How can biotech companies avoid buying disconnected security tools?
Biotech companies avoid buying disconnected security tools by developing a security strategy before selecting technologies. Security architectures should support laboratory environments, cloud services, collaboration platforms, and compliance requirements without creating unnecessary operational complexity.
Effective planning focuses on:
- Defining security priorities
- Identifying critical assets
- Evaluating integration requirements
- Reducing duplicate functionality
- Improving operational visibility
- Supporting long-term scalability
Organizations frequently work with advisors, consultants, or providers, such as Single Point of Contact, to evaluate technology stacks and identify opportunities to simplify operations. Better alignment between tools and objectives helps reduce complexity while improving overall security effectiveness.
What role does continuous monitoring play in third-party risk management?
Continuous monitoring helps organizations identify security concerns involving vendor access, shared systems, cloud environments, and sensitive information before issues escalate.
Monitoring activities commonly include:
- User activity review
- Authentication analysis
- Access validation
- Alert investigation
- Configuration assessment
- Data movement analysis
Ongoing oversight helps organizations understand how external entities interact with critical systems and supports earlier identification of unusual behavior that could affect research programs or business operations.
What vendor cybersecurity requirements should biotech companies include in contracts?
Biotech companies should include cybersecurity requirements in vendor contracts that define security responsibilities, data protection expectations, incident response obligations, and oversight rights. Contractual requirements help reduce ambiguity and establish accountability for third parties that access sensitive information, regulated systems, or critical business operations.
Common requirements include:
- Security control expectations
- Multi-factor authentication requirements
- Data encryption standards
- Incident notification timelines
- Access management procedures
- Audit and assessment rights
- Data retention requirements
- Subcontractor oversight obligations
- Compliance responsibilities
- Security reporting expectations
Contracts should address how vendors protect research data, intellectual property, clinical information, Laboratory Information Management Systems (LIMS), Electronic Laboratory Notebooks (ELN), and other sensitive assets. Clearly defined requirements help strengthen third-party governance and reduce risk throughout the vendor relationship lifecycle.
Reducing cybersecurity risk across biotech vendor relationships
Third-party relationships are essential to modern biotech operations, but they also introduce cybersecurity challenges that require careful oversight. Effective programs combine governance, access management, risk assessments, monitoring, documentation, and vendor accountability practices that help protect sensitive information and support business objectives.
Organizations that understand where external parties interact with systems, data, and workflows are better positioned to reduce risk, strengthen collaboration, and maintain confidence across research, operational, and commercial activities.
Where can biotech companies learn more about managed security providers?
Organizations can learn how managed security services support biotech environments through Single Point of Contact’s biotech IT and security services. Services include 24×7 monitoring, threat detection, incident response, compliance support, Microsoft 365 security, and protection of research data and intellectual property.
Related Articles
How can biotech companies detect and respond to ransomware?
Ransomware can disrupt research timelines, compromise scientific data, and impact laboratory operations. Learn how biotech companies detect ransomware early, contain threats, protect endpoints, strengthen backup strategies, and improve incident response readiness across research, cloud, and regulated environments.
Biotech managed security resource center
This hub provides an overview of biotech cybersecurity, including managed security services, MDR, managed SOC, security operations maturity, intellectual property protection, ransomware preparedness, compliance requirements, audit readiness, vendor risk management, and strategies for securing research environments.
Biotech cybersecurity services overview
This page provides an overview of cybersecurity, compliance, cloud, and managed IT services for biotech companies. Learn how life sciences organizations protect research data, support laboratory environments, strengthen operational resilience, meet regulatory requirements, and align technology strategies with scientific and business objectives.
Frequently asked questions
Are CROs considered third-party cybersecurity risks?
Yes. CROs frequently receive access to research systems, study data, and proprietary information, making governance and security reviews important components of risk management. Any organization with access to sensitive information or business systems can introduce cybersecurity risk if appropriate controls, oversight, and governance practices are not in place.
What information should biotech companies request from vendors during security reviews?
Organizations frequently request security policies, compliance certifications, incident response procedures, vulnerability management practices, access control standards, and evidence of cybersecurity governance. These materials help evaluate whether a vendor’s security program aligns with organizational expectations. Additional requests may include penetration testing summaries, cyber insurance information, and third-party assessment results.
Can a cybersecurity issue affect partnership opportunities?
Yes. Security concerns discovered during due diligence reviews can delay partnerships, licensing discussions, acquisitions, investments, or other strategic initiatives. Strong governance and documented controls help demonstrate operational maturity and reduce concerns during evaluations. Common activities include monitoring vendor access, reviewing authentication activity, and supporting incident investigations involving third-party environments.
Can managed security services help with third-party risk management?
Managed security providers, such as Single Point of Contact, can help support monitoring, vendor oversight, access reviews, incident response activities, and reporting efforts that contribute to broader third-party risk management programs.
How often should biotech companies review vendor cybersecurity risks?
Most organizations perform reviews annually and whenever significant changes occur involving vendors, technologies, data-sharing arrangements, acquisitions, or business operations. Higher-risk providers may warrant more frequent evaluations and ongoing oversight activities.
About the author
Gregory Morawietz is a technology executive with experience evaluating and comparing IT and security service models. He helps organizations understand trade-offs among delivery models in terms of cost, scalability, and operational impact. His work includes supporting organizations in regulated industries such as life sciences, healthcare, and technology. Gregory brings a structured, practical perspective to the comparison of technologies and service models in a complex and evolving landscape.